Recursion Pharma Form 4: 84,925 RSUs; 169,851 options granted

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) reported an insider equity award on 11/05/2025. A director and officer (Chief R&D Commercial Officer) received 84,925 Class A RSUs at $0 and a stock option for 169,851 shares at an exercise price of $4.96. The RSUs vest 1/16 on February 15, 2026 and every three months thereafter; the option vests 1/48 starting December 5, 2025 with monthly installments thereafter. Following the awards, direct ownership was 753,122 Class A shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Khan Najat

Role Chief R&D Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	169,851	$0.00	--
Grant/Award	Class A Common Stock	84,925	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 169,851 shares (Direct); Class A Common Stock — 753,122 shares (Direct)

Footnotes (1)

1. This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on February 15, 2026, and every three months thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/05/2025		A(1)		84,925	A	$0	753,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.96	11/05/2025		A		169,851		(2)	11/05/2035	Class A Common Stock	169,851	$0	169,851	D

Explanation of Responses:

1. This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on February 15, 2026, and every three months thereafter.

2. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RXRX disclose in this Form 4?

An insider received 84,925 RSUs at $0 and a stock option for 169,851 shares with an exercise price of $4.96 on 11/05/2025.

What are the vesting terms for the RXRX RSUs?

The 84,925 RSUs vest as to 1/16 on February 15, 2026 and every three months thereafter.

What are the vesting terms for the RXRX stock options?

The 169,851 options vest 1/48 starting on December 5, 2025, with monthly vesting thereafter.

What is the exercise price of the options reported by RXRX?

The stock option has an exercise price of $4.96 per share.

How many RXRX shares did the insider own after these grants?

Direct beneficial ownership was 753,122 Class A shares following the reported transactions.

What role does the reporting person hold at RXRX?

The individual is both a Director and an Officer, with the title Chief R&D Commercial Officer.